Literature DB >> 29311124

Interferon β for Multiple Sclerosis.

Dejan Jakimovski1, Channa Kolb2, Murali Ramanathan2,3, Robert Zivadinov1,4, Bianca Weinstock-Guttman2.   

Abstract

Despite that the availability of new therapeutic options has expanded the multiple sclerosis (MS) disease-modifying therapy arsenal, interferon β (IFN-β) remains an important therapy option in the current decision-making process. This review will summarize the present knowledge of IFN-β mechanism of action, the overall safety, and the short- and long-term efficacy of its use in relapsing remitting MS and clinically isolated syndromes. Data on secondary progressive MS is also provided, although no clear benefit was identified.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29311124     DOI: 10.1101/cshperspect.a032003

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  32 in total

1.  Multiplexed Gene Expression as a Characterization of Bioactivity for Interferon Beta (IFN-β) Biosimilar Candidates: Impact of Innate Immune Response Modulating Impurities (IIRMIs).

Authors:  Eduardo F Mufarrege; Lydia A Haile; Marina Etcheverrigaray; Daniela I Verthelyi
Journal:  AAPS J       Date:  2019-02-08       Impact factor: 4.009

Review 2.  Shared and Distinct Functions of Type I and Type III Interferons.

Authors:  Helen M Lazear; John W Schoggins; Michael S Diamond
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 3.  Therapeutic Advances in Multiple Sclerosis.

Authors:  Jennifer H Yang; Torge Rempe; Natalie Whitmire; Anastasie Dunn-Pirio; Jennifer S Graves
Journal:  Front Neurol       Date:  2022-06-03       Impact factor: 4.086

4.  The lung microbiome regulates brain autoimmunity.

Authors:  Alexander Flügel; Francesca Odoardi; Leon Hosang; Roger Cugota Canals; Felicia Joy van der Flier; Jacqueline Hollensteiner; Rolf Daniel
Journal:  Nature       Date:  2022-02-23       Impact factor: 69.504

Review 5.  Neuroimmunometabolism: A New Pathological Nexus Underlying Neurodegenerative Disorders.

Authors:  Swarup Mitra; Avijit Banik; Sumit Saurabh; Malabika Maulik; Shailesh N Khatri
Journal:  J Neurosci       Date:  2022-01-13       Impact factor: 6.709

Review 6.  The science and medicine of human immunology.

Authors:  Bali Pulendran; Mark M Davis
Journal:  Science       Date:  2020-09-25       Impact factor: 47.728

7.  TLR3-driven IFN-β antagonizes STAT5-activating cytokines and suppresses innate type 2 response in the lung.

Authors:  Rinna Tei; Koji Iijima; Koji Matsumoto; Takao Kobayashi; Jyoti Lama; Elizabeth A Jacobsen; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2021-08-21       Impact factor: 10.793

Review 8.  Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review.

Authors:  Carmen Adella Sirbu; Elena Dantes; Cristina Florentina Plesa; Any Docu Axelerad; Minerva Claudia Ghinescu
Journal:  Medicina (Kaunas)       Date:  2020-04-24       Impact factor: 2.430

9.  Type 1 interferons as a potential treatment against COVID-19.

Authors:  Erwan Sallard; François-Xavier Lescure; Yazdan Yazdanpanah; France Mentre; Nathan Peiffer-Smadja
Journal:  Antiviral Res       Date:  2020-04-07       Impact factor: 5.970

10.  Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner.

Authors:  Pei-Ming Yang; Yao-Yu Hsieh; Jia-Ling Du; Shih-Chieh Yen; Chien-Fu Hung
Journal:  Biomolecules       Date:  2020-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.